Logo Image
|Videos|October 16, 2017

APX001: A New Antifungal with Activity Against Candida auris

Ciara Kennedy, PhD, breaks down APX001, a new antifungal with a unique mechanism of action.

Ciara Kennedy, PhD, president and CEO of Amplyx Pharmaceuticals, Inc, explains that by targeting an enzyme with the fungal cell, APX001 is able to inhibit the formation of the fungal cell wall, thereby decreasing the virulence, pathogenicity, and biofilm-producing capabilities of the fungus. Data from phase 1 studies are promising for this new antifungal to be able to be administered in both intravenous and oral forms, providing physicians with a new opportunity for continuum of care, using the same mechanism of action.

Related to this article

View more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more